Rechercher des projets européens

26 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders (COSYN)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

COSYN integrates outstanding European academic and three large Pharma to exploit genomic findings for intellectual disability (ID), autism, and schizophrenia. We capitalise on comorbidity, from clinic to cells and synapses, and have access to large existing samples. We focus on rare genetic variants of strong effect in patients with clinical comorbidity. Our aims are: (1) Understand comorbidity by ...
Voir le projet

 14

 TERMINÉ 

Training, Research and Raising of Public Awareness in Cell Biology and Pathology of Neuroglia (EU-GliaPhD)

Date du début: 1 déc. 2016, Date de fin: 30 nov. 2020,

The research in which the young scientists of the EU-GliaPhD consortium will be trained is centred on the role of neuron-glia interactions in brain function and pathology.Prompted by exciting discoveries of recent years, many academic research groups are currently focussing their research on the field of neuron-glia interactions for a better understanding of brain function. Also the private sector ...
Voir le projet

 13

 TERMINÉ 

Pharmaceutical Education And Research with Regulatory Links: Innovative drug development strategies and regulatory tools tailored to facilitate earlier access to medicines (PEARRL)

Date du début: 1 mai 2016, Date de fin: 30 avr. 2020,

The European Pharma industry is a major contributor to EU well-being, both in public health and economic (sales >200 billion €/year) terms. To maintain global leadership, it must respond to challenges from low-cost producers e.g. China by bringing new drug molecules to market in a streamlined, cost-effective manner. This strategy is underscored by recent initiatives of European regulators to exped ...
Voir le projet

 9

 TERMINÉ 

Clinical study in Parkinson's disease with two unique goals: 1) Proof-of-concept of CDNF protein for disease modification; 2) Validation of clinically tested device for intracerebral drug delivery (TreatER)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2019,

The main focus of TreatER is conducting a randomized, placebo-controlled, first-in-human, proof-of-concept, safety and efficacy study of intracerebrally administered CDNF protein therapy in patients with Parkinson’s disease (PD), using a neurosurgically implanted Drug Delivery System (DDS), which will also be clinically validated in the study. Thus the TreatER project has two independent goals, ei ...
Voir le projet

 12

 TERMINÉ 

European Prevention of Alzheimer’s Dementia Consortium (EPAD)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,

Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions. To achieve this, EPAD will also provide the analytical infras ...
Voir le projet

 40

 TERMINÉ 

Training the Next Generation of European Visual Neuroscientistsfor the benefit of innovation in health care and high-tech industry (NextGenVis)

Date du début: 1 mars 2015, Date de fin: 28 févr. 2019,

The human visual brain can learn and adapt to change, which solves many of the problems posed by an ever-changing visual environment. However, to maintain a consistent overall representation of the visual world, the brain also has to retain previously acquired neuronal mechanisms. The key is to strike a balance between plasticity and stability.Increasing our knowledge about the stability and plast ...
Voir le projet

 10

 TERMINÉ 

European Lead Factory (EUC²LID)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

...ransition of the European Lead Factory into a novel sustainable business model, facilitating future public-private alliances based on pre-competitive, community-based efforts in early drug research.
Voir le projet

 34

 TERMINÉ 

Delivering European Translational Information & Knowledge Management Services (ETRIKS)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive translational research and are employing integrative analysis approaches to achieve their goals. Although a common KM platform for IMI projects was envisioned in the original IMI Strategic Research Agenda it has not yet been implemented. The lack of a common p ...
Voir le projet

 17

 TERMINÉ 

Oral biopharmaceutics tools (ORBITO)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will ...
Voir le projet

 28

 TERMINÉ 

Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes (TACTICS)

Date du début: 1 janv. 2012, Date de fin: 30 juin 2017,

Compulsivity is characterized by a repetitive, irresistible urge to perform a behavior, the experience of loss of voluntary control over this intense urge, the diminished ability to delay or inhibit thoughts or behaviors, and the tendency to perform repetitive acts in a habitual or stereotyped manner. Compulsivity is a cross-disorder trait underlying phenotypically distinct psychiatric disorders t ...
Voir le projet

 13

 TERMINÉ 

Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys ...
Voir le projet

 29

 TERMINÉ 

Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities (ETOX)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2016,

The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modell ...
Voir le projet

 30

 TERMINÉ 

European Bank for induced pluripotent Stem Cells (EBISC)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2016,

EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to establish subsequently for Europe a centralised, not-for-profit bank providing all qualified users with access to scalable, cos ...
Voir le projet

 30

 TERMINÉ 

European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)

Date du début: 1 janv. 2010, Date de fin: 30 nov. 2016,

Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Voir le projet

 34

 TERMINÉ 

European Medicines Research Training Network (EMTRAIN)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2016,

EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will establish a pan-European platform of excellence for education and training covering the whole life-cycle of medicines from basic research through clinical development to pharmaco-vigilance. It will underpin the successful delivery of the current and future IMI-f ...
Voir le projet

 32

 TERMINÉ 

European programme in Pharmacovigilance and Pharmacoepidemiology (EU2P)

Date du début: 1 sept. 2009, Date de fin: 30 juin 2016,

The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia at the European level. It will give access to a harmonised training programme that gathers complementary specialized and eminent European partners. The Eu2P consortium consists of course providers with aproven record including the University of Bordeaux (Eu2P ...
Voir le projet

 24

 TERMINÉ 

The Open Pharmacological Concepts Triple Store (OPEN PHACTS)

Date du début: 1 mars 2011, Date de fin: 29 févr. 2016,

...ificant waste and an opportunity cost.To address these challenges, the Open PHACTS project will develop an open access innovation platform, Open Pharmacological Space (OPS), via a semantic web approach. OPS will comprise data, vocabularies and infrastructure needed to accelerate drug-oriented research. This semantic integration hub will remove key bottlenecks in small molecule drug discovery: disp ...
Voir le projet

 32

 TERMINÉ 

Novel Statistical Methodology for Diagnostic/Prognostic and Therapeutic Studies and Systematic Reviews (MEDIASRES)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,

... approach of the network. The collaboration of leading biostatistical experts will stimulate the discovery of promising statistical methodology useful for the design and analysis of clinical research. The integration of full industry partners and clinical advisors in the network enables optimal conditions for research driven by application, which will ensure tangible benefits of the programme."
Voir le projet

 10

 TERMINÉ 

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development (PHARMA-COG)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2015,

PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision bef ...
Voir le projet

 38

 TERMINÉ 

Understanding chronic pain and improving its treatment (EUROPAIN)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2015,

We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational research which will: 1) increase the understanding of chronic pain mechanisms; 2)facilitate the development of novel analgesic drugs; and 3) improve the treatment of chronic pain patients.Nineteen researchers drawn from the London Pain Consortium, the Danish Pain Re ...
Voir le projet

 29

 TERMINÉ 

bioMARkers and molecular tumor classification for non-genotoxic CARcinogenesis (MARCAR)

Date du début: 1 janv. 2010, Date de fin: 30 juin 2015,

MARCAR aims to establish reliable early markers and molecular classification of tumors in non genotoxic carcinogenesis, applying a mechanism-based approach. Benefits are improved drug safety, more efficient drug development, and progress with 3 R issues. MARCAR focuses on rodent liver, the major target organ of non-genotoxic carcinogens (NGC). However, this approach will facilitate predictions for ...
Voir le projet

 12

 TERMINÉ 

Pharmacoepidemiolocal Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT)

Date du début: 1 sept. 2009, Date de fin: 30 avr. 2015,

Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs. Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Age ...
Voir le projet

 36

 TERMINÉ 

TreatPolyQ – Industrial Academic Initial Training Network towards treatment of Polyglutamine Diseases (TREATPOLYQ)

Date du début: 1 mars 2011, Date de fin: 28 févr. 2015,

Protein aggregation is a hallmark of many late onset neurodegenerative disorders including Parkinson’s Disease (PD), Alzheimer’s Disease (AD), amyotrophic lateral sclerosis (ALS), prion diseases as well as the group of polyglutamine diseases (polyQ). The aim of this proposal is to create a network of European partners bridging important basic mechanisms involved in proteinopathies, research of mod ...
Voir le projet

 17

 TERMINÉ 

Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS)

Date du début: 1 sept. 2009, Date de fin: 28 févr. 2015,

Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical ...
Voir le projet

 20

 TERMINÉ 

Development of a novel FGL therapy and translational tests for regenerative treatment of neurological disorders (NEUROFGL)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2014,

Neurodegenerative disorders such as, Alzheimer’s disease (AD), Mild Cognitive Impairment (MCI), stroke, Traumatic Brain Injury (TBI) and chronic stress create a major economic burden to society and a substantial reduction in quality of life for patients and families. The development of neuroregenerative therapies is notoriously difficult and requires significant investment. NeuroFGL will contribut ...
Voir le projet

 7

 TERMINÉ 

Embryonic Stem cell-based Novel Alternative Testing Strategies (ESNATS)

Date du début: 1 avr. 2008, Date de fin: 30 sept. 2013,

"ESNATS aims at developing a novel toxicity test platform based on embryonic stem cells (ESC), especially human ESC (hESC), to accelerate drug development, reduce R&D costs and propose a powerful alternative to animal tests (3 Rs). ESNATS will address current drug-testing shortcomings: - testing takes place late in the development cycle - animal test systems bear the risk of non-prediction due to ...
Voir le projet

 34